Related references
Note: Only part of the references are listed.Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
L. L. Remsing Rix et al.
LEUKEMIA (2009)
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
Jonathan A. Winger et al.
BMC STRUCTURAL BIOLOGY (2009)
Eph-ephrin bidirectional signaling in physiology and disease
Elena B. Pasquale
CELL (2008)
ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression
Dakshina M. Jandhyala et al.
CELLULAR MICROBIOLOGY (2008)
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib
Elizabeth Day et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia
Claire Villalva et al.
LEUKEMIA & LYMPHOMA (2008)
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis
X. Leng et al.
ONCOGENE (2008)
Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity?
Martin Lackmann et al.
SCIENCE SIGNALING (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406
Jingxuan Pan et al.
CANCER SCIENCE (2007)
Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives
Tatsuya Horio et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
Asumi Yokota et al.
BLOOD (2007)
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity
Ellen Weisberg et al.
GASTROENTEROLOGY (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
S Kimura et al.
BLOOD (2005)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA
XS Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics
RC Ireton et al.
CURRENT CANCER DRUG TARGETS (2005)
ZAK re-programs atrial natriuretic factor expression and induces hypertrophic growth in H9c2 cardiomyoblast cells
CY Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells
A Ptasznik et al.
NATURE MEDICINE (2004)
A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase a in neoplastic cell transformation and tumor development
YY Cho et al.
CANCER RESEARCH (2004)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation
DL Smith et al.
MOLECULAR & CELLULAR PROTEOMICS (2002)
Share Paper
